DK108589D0 - Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer - Google Patents

Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer

Info

Publication number
DK108589D0
DK108589D0 DK108589A DK108589A DK108589D0 DK 108589 D0 DK108589 D0 DK 108589D0 DK 108589 A DK108589 A DK 108589A DK 108589 A DK108589 A DK 108589A DK 108589 D0 DK108589 D0 DK 108589D0
Authority
DK
Denmark
Prior art keywords
antibodies
chimerary
humant
dna sequences
sequences coding
Prior art date
Application number
DK108589A
Other languages
English (en)
Other versions
DK108589A (da
Inventor
Dennis J Carlo
Gary Samuel David
Mary Jaqueline Johnson
Catherine Brautigam Beidler
James Richard Ludwig
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of DK108589D0 publication Critical patent/DK108589D0/da
Publication of DK108589A publication Critical patent/DK108589A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK108589A 1988-03-09 1989-03-07 Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer DK108589A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16585688A 1988-03-09 1988-03-09
US27257788A 1988-11-17 1988-11-17

Publications (2)

Publication Number Publication Date
DK108589D0 true DK108589D0 (da) 1989-03-07
DK108589A DK108589A (da) 1989-09-22

Family

ID=26861757

Family Applications (1)

Application Number Title Priority Date Filing Date
DK108589A DK108589A (da) 1988-03-09 1989-03-07 Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer

Country Status (5)

Country Link
EP (1) EP0332424A3 (da)
JP (1) JPH029371A (da)
AU (1) AU618990B2 (da)
DK (1) DK108589A (da)
IL (1) IL89489A0 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
US5081235A (en) * 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
JPH03206886A (ja) * 1989-11-13 1991-09-10 Green Cross Corp:The ヒト腫瘍細胞抗原に対し特異性を持つマウス―ヒトキメラａ１０抗体
GB2276169A (en) * 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE69321218T2 (de) * 1992-02-19 1999-02-18 Schering Corp., Kenilworth, N.J. Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6380979B1 (en) * 1996-07-02 2002-04-30 Matsushita Electric Industrial Co., Ltd. Scanning line converting circuit and interpolation coefficient generating circuit
EP2042194A3 (en) 1999-05-14 2009-04-22 Imclone Systems, Inc. Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7071319B2 (en) 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
RU2272809C2 (ru) 2000-05-16 2006-03-27 Томас Джефферсон Юниверсити Специфичные в отношении вируса бешенства нейтрализующие моноклональные антитела человека и нуклеиновые кислоты и связанные с ними способы
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
BRPI0312818B8 (pt) 2002-07-19 2021-05-25 Beth Israel Deaconess Medical Ct Inc uso de uma medida do nível do polipeptídeo sflt-1 em uma amostra de uma paciente e uso de uma medida dos níveis de pelo menos dois dos peptídeos sflt1, vegf livre ou polipeptídio pigf livre em uma amostra de um paciente usando um métrico
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2005090407A1 (en) 2004-03-19 2005-09-29 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
WO2006021893A2 (en) 2004-08-26 2006-03-02 The University Of Western Ontario Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, fn staphylococcus aureus
WO2006034507A2 (en) 2004-09-24 2006-03-30 Beth Israel - Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
DK1819358T3 (da) 2004-11-18 2014-10-27 Imclone Llc Antistoffer mod vaskulær endothel-vækstfaktor-receptor-1
US7598043B2 (en) 2004-11-19 2009-10-06 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
KR101246504B1 (ko) 2005-06-17 2013-03-26 임클론 엘엘씨 항－ＰＤＧＦＲα 항체
BRPI0617057A2 (pt) 2005-08-30 2011-07-12 Univ Miami anticorpo isolado, toxina especìfica para receptor de fator de necrose tumoral 25 (tnfr25), método para ativar o receptor de fator de necrose tumoral 25 (tnfr25), método para inibir a sinalização do receptor de fator de necrose tumoral 25 (tnfr25) numa célula, vacina antitumoral, método para imunizar um paciente contra tumor, método para tratar cáncer num paciente, método para tratar e/ou prevenir inflamação intestinal, composição terapêutica para a facilitação de um transplante de órgão, método para transplantar um tecido de um doador para um hospedeiro, método para inibir a expressão clonal de uma população de células t cd8 cognatas, método para tratar e/ou prevenir inflamação pulmonar, antagonista de tnfr25 isolado, composição e vetor de expressão
EA020324B1 (ru) 2006-07-18 2014-10-30 Санофи-Авентис АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
PE20090993A1 (es) 2007-08-29 2009-07-08 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US7951370B2 (en) 2008-03-12 2011-05-31 Imclone Llc Anti-TYRP1 antibodies
KR101442323B1 (ko) 2008-09-07 2014-09-25 글라이코넥스 인코포레이티드 항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
CN102712945B (zh) 2009-08-18 2016-11-02 哈佛大学校长及研究员协会 治疗增殖性疾病和病原性疾病的方法和组合物
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
EP2501722A4 (en) * 2009-11-19 2013-05-01 Univ Singapore METHOD FOR PRODUCING T-CELL-RECEPTOR-SIMILAR MONOCLONAL ANTIBODIES AND APPLICATIONS THEREOF
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
US9375473B2 (en) 2010-02-19 2016-06-28 Cornell Research Foundation, Inc. Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
CA2858350A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
TWI745962B (zh) 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法
DE202014008375U1 (de) 2014-10-18 2015-11-26 Reinz-Dichtungs-Gmbh Seperatorplatte und elektrochemisches System
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
WO2019217450A1 (en) 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
JP7784898B2 (ja) 2019-05-24 2025-12-12 サノフイ 全身性硬化症を治療するための方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
IL89490A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Chimeric antibodies directed against metal chelates

Also Published As

Publication number Publication date
DK108589A (da) 1989-09-22
EP0332424A3 (en) 1991-07-03
IL89489A0 (en) 1989-09-10
JPH029371A (ja) 1990-01-12
AU618990B2 (en) 1992-01-16
EP0332424A2 (en) 1989-09-13
AU3107289A (en) 1989-09-14

Similar Documents

Publication Publication Date Title
DK108589A (da) Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer
DK108189D0 (da) Chimere antistoffer rettet mod humant carcinoembryonalt antigen og metal-chelater samt dna-sekvenser, der koder for saadanne antistoffer
DK296189A (da) Nucleinsyresekvenser, som koder for peptidsekvenser af carcinoembryonisk antigen-familien
DE68924227D1 (de) DNA-Fragment.
DE3879452D1 (de) Chimaere antikoerper.
NO891818L (no) T4-reseptor-protein, relaterte dna-sekvenser samt fremstilling derav.
DE68907519D1 (de) Biosensoren.
NO892612D0 (no) Gruspakningssystem.
FI962247L (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
DE68922772D1 (de) Verfahren zur Zeichenkettenermittlung.
DK38989A (da) Dna-sekvens
NO884377D0 (no) Doserings-/blandesproeyte.
NO892294D0 (no) Polypeptidforbindelser.
DE68914933D1 (de) Abrasionsprüfgeräte.
DE58908164D1 (de) Füllelement.
NO881384L (no) Peptider.
FI892357L (fi) Pressad spole.
NO885108D0 (no) Peptider.
FI873478A7 (fi) Karsinoembryomaista antigeeniä koodaava cDNA.
IT8821556A0 (it) Peptidi immunostimolanti.
DE68908979D1 (de) Proben-Einspritzvorrichtung.
FI902803A7 (fi) DNA-sekvenssi, joka koodaa a-amylaasi-pullulanaasientsyymiä
FI894069A7 (fi) Sulfonamidoalkyl -cykloalkanfoereningar, foerfarande foer framstaellning daerav samt laekemedel.
DK324287A (da) Antistof mod koensspecifikt antigen
FI891308A7 (fi) Uudet polypeptidit, joilla on kasvutekijäaktiivisuutta sekä polypeptideitä koodittavat nukleiinihapposekvenssit

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment